NL-OMON23469已完成不适用
A multicenter, prospective study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis.
Stichting Hemato-Oncologie voor Volwassenen Nederland(HOVON), HOVON Data Center0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
PMID: 30923094
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Biopsy proven, systemic, untreated AL amyloidosis requiring systemic chemotherapy;
- •2. Age 18 -70 years inclusive at the time of signing the informed consent form;
排除标准
- •1. Multiple Myeloma stage II and III (Durie and Salmon);
- •2. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form;
研究者
相似试验
进行中（未招募）
1 期
A study to investigated whether bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-DEHOVON Foundation50
进行中（未招募）
1 期
A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-NLHOVON Foundation50
Unknown
2 期
Bortezomib Maintenance in High Risk DLBCLDiffuse Large B Cell LymphomaNCT01965977Samsung Medical Center59
进行中（未招募）
不适用
A PHASE II, MULTI-CENTER STUDY OF BORTEZOMIB, ADRIAMYCIN, DEXAMETHASONE (PAD) as induction and MELPHALAN 100 mg/m2 (MEL 100) as transplant, IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.Treatment in elderly newly diagnosed multiple myeloma patientsMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2005-004714-32-ITFONDAZIONE NEOPLASIE SANGUE ONLUS
Unknown
不适用
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.Multiple MyelomaNCT02797041IRCCS Centro di Riferimento Oncologico della Basilicata100